- Home
- PRE vs EVMN Comparison
PRE vs EVMN Comparison
Compare PRE & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRE | EVMN |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.6M | 284.5M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PRE | EVMN |
|---|---|---|
| Price | $17.00 | $8.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $38.44 | $22.78 |
| AVG Volume (30 Days) | 172.6K | ★ 899.6K |
| Earning Date | 11-18-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | $142.73 | N/A |
| Revenue Next Year | $81.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $11.37 | $4.94 |
| 52 Week High | $27.24 | $33.20 |
Technical Indicators
Market Signals| Indicator | PRE | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 62.66 |
| Support Level | $15.09 | $4.94 |
| Resistance Level | $19.68 | $13.35 |
| Average True Range (ATR) | 1.29 | 0.78 |
| MACD | 0.16 | 0.44 |
| Stochastic Oscillator | 50.44 | 81.36 |
Price Performance
Historical ComparisonAbout PRE Prenetics Global Limited
Prenetics Global Ltd is a consumer health and wellness company offering nutrition and longevity products through its flagship brand, IM8. It offers science-backed daily nutrition and longevity products distributed directly to consumers across multiple countries. The company's products are developed with scientific input and are subject to third-party quality certifications.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.